[6-K] Haleon plc American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon has completed a tranche of its announced share buyback, purchasing 830,000 ordinary shares for cancellation on 13 August 2025 at a volume-weighted average price of 356.7308p. The purchases on the London Stock Exchange ranged between 354.7000p and 358.6000p.

After settlement the company reports a registered share capital of 8,976,305,788 ordinary shares, of which 3,880,205 are held in treasury, leaving 8,972,425,583 voting shares. A full trade breakdown is available from the company’s announcement link and on its investor website.

Insights

Equity Analyst

TL;DR: The repurchase is executed as planned but is immaterial to capital structure; it signals ongoing buyback activity.

The company purchased 830,000 shares at a VWAP of 356.7308p, representing roughly 0.009% of the registered share capital (830,000 of 8,976,305,788). The disclosed post-settlement voting shares are 8,972,425,583. The cash outlay implied by the VWAP is approximately £2.96 million. From an equity perspective, this tranche will have a negligible impact on per-share metrics but demonstrates the company’s continued execution of its announced buyback programme.

Corporate Governance Expert

TL;DR: Transaction follows the announced programme and maintains transparency through provided trade breakdown; no governance concerns apparent.

The announcement details an open-market purchase for cancellation and provides a link to the full trade breakdown in line with regulatory requirements. The updated counts show 3,880,205 treasury shares and 8,972,425,583 voting shares, figures shareholders should use for notification thresholds. The size of the tranche is very small relative to total share capital, so it does not materially alter shareholder control or disclosure thresholds.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒    Form 40-F ☐                        

EXHIBIT INDEX

Exhibit Number	Description
99.1	14 August 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

14 August 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 830,000 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	13 August 2025	13 August 2025	13 August 2025
Number of Shares purchased:	830,000	-	-
Highest price paid per Share (p):	358.6000	-	-
Lowest price paid per Share (p):	354.7000	-	-
Volume weighted average price paid per Share (p):	356.7308	-	-

Following the settlement of the above, the Company's registered share capital is 8,976,305,788 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,972,425,583 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/2483V_1-2025-8-13.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: August 14, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

What did Haleon (HLN) announce in this Form 6-K?

Haleon announced the purchase of 830,000 ordinary shares for cancellation under the second tranche of its buyback programme.

At what price were the shares bought by Haleon (HLN)?

Purchases on the London Stock Exchange ranged from 354.7000p to 358.6000p with a VWAP of 356.7308p.

How many voting shares does Haleon have after settlement?

After settlement there are 8,972,425,583 ordinary shares with voting rights.

How many shares does Haleon hold as treasury shares?

The company holds 3,880,205 shares as treasury shares following this transaction.

Where can I find a full breakdown of the individual trades?

A full breakdown is available at the company-provided link: http://www.rns-pdf.londonstockexchange.com/rns/2483V_1-2025-8-13.pdf and on www.haleon.com/investors.